General Announcement::Glenmark receives ANDA approval for Icatibant Injection Single Dose Prefilled Syringe

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
24-May-2021 13:32:00
Status
New
Announcement Sub Title
Glenmark receives ANDA approval for Icatibant Injection Single Dose Prefilled Syringe
Announcement Reference
SG210524OTHRIKLT
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
24/05/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/ 3 mL (10 mg/mL) Single-Dose Prefilled Syringe

Attachments

SGX PR_24052021.pdf
Total size =599K